Carmot Therapeutics, Inc.

Carmot Therapeutics, Inc. is a biotechnology company focused on innovative drug discovery and development using its proprietary platform to enhance therapeutic strategies for various diseases. Founded in 2008 and headquartered in Berkeley, US, Carmot Therapeutics, Inc. specializes in drug discovery and development.

The company was established by Stig Hansen and has undergone significant transformations in its operational strategies. The company has engaged in 11 deals, with the most recent deal occurring on December 3, 2023. Carmot Therapeutics raised a total of USD 151. 70 mn, with its latest funding round being an Add-on at USD 2.

70 bn, led by Roche. Carmot Therapeutics focuses on advancing drug discovery through its innovative platform that leverages unique screening technologies. Their services aim to identify and optimize small molecules for various therapeutic targets, providing solutions that facilitate the development of novel pharmaceuticals. This includes work on cardiovascular and metabolic diseases, with a keen emphasis on enhancing R&D processes for pharmaceutical companies.

For the year 2022, Carmot Therapeutics reported an EBITDA of USD -42. 79 mn, reflecting the company's ongoing investment in research and development. Looking ahead, Carmot Therapeutics plans to leverage the recent acquisition by F. Hoffmann-La Roche Ltd to enhance its research and development capabilities.

The acquisition is intended to strengthen Roche's portfolio in cardiovascular and metabolic diseases, with an additional USD 400 mn available upon achieving specific milestones. This strategic move is anticipated to expand Carmot's reach in new markets, particularly in North America and Europe, as it continues to develop clinical-stage incretin programs.